Evidence map›Paper›PMID 41102542›Full record

ArticleInsights into imaging2025

Can ADC changes help mRECIST or LI-RADS treatment response algorithm better diagnose pathological response of HCC after preoperative radiotherapy? Secondary analysis of a prospective phase 2 trial.

Rong Cong, Fan Wu, Yirui Zhai, Feng Ye, Shuang Wang, Zhaowei Chen, Bing Feng, Leyao Wang, Yongjian Zhu, Sicong Wang and 3 more

Abstract read
In one paragraph

Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rong Cong *Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Fan Wu *Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yirui Zhai *Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Feng YeDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shuang WangDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhaowei ChenDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bing FengDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Leyao WangDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yongjian ZhuDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sicong WangGeneral Electric Healthcare (China), Beijing, China.
Xinming ZhaoDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bo ChenDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. chenboo@outlook.com.
Xiaohong MaDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. maxiaohong@cicams.ac.cn.ORCID http://orcid.org/0000-0002-9048-8374

Funding

Beijing Hope Run Special Fund of Cancer Foundation of China LC2022A14CAMS Innovation Fund for Medical Sciences 2021-I2M-1-066 and 2022-I2M-C&T-B-062
6 · The paper itself

Abstract

objectivesTo explore the role of apparent diffusion coefficient (ADC) changes in predicting pathological response to preoperative radiotherapy (RT) in hepatocellular carcinoma (HCC) compared to existing evaluation criteria, using histopathology as the reference standard. MATERIALS AND

methodsBuilding on the prospective clinical trial, we included 35 patients with 38 HCCs who underwent preoperative RT followed by hepatectomy between December 2014 and January 2019. Pre- and post-RT ADC parameters (ADC

resultsADC values, interquartile range, range, variance, mean absolute deviation, robust mean absolute deviation, and root mean squared increased; energy and total energy decreased; and skewness developed into negative skewness after RT. Higher Δ-ADC

conclusionsADC changes have the potential to predict the pathological response of HCC to preoperative RT, thereby enhancing current evaluation criteria. Integration of Δ-ADC CRITICAL RELEVANCE STATEMENT: Δ-ADC KEY POINTS: Precise assessment of hepatocellular carcinoma response is required for patients undergoing preoperative radiotherapy. Radiotherapy induced an increase in ADC values and heightened intratumoral heterogeneity. As the delineated region of interest expanded, AUC decreased and inter-observer agreement increased. Δ-ADC

Indexed as

Apparent diffusion coefficientHepatocellular carcinomaMagnetic resonance imagingRadiotherapyResponse evaluation

Identifiers

PMID41102542
PMCPMC12532537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.